29-month follow-up from checkmate 648: nivolumab combination therapy in escc
Published 1 year ago • 181 plays • Length 1:19Download video MP4
Download video MP3
Similar videos
-
1:01
long-term efficacy of nivolumab combinations in advanced escc in checkmate 648
-
0:37
45-month checkmate 648 results show nivolumab combos' sustained benefits in escc
-
4:51
expanded efficacy and safety analyses from checkmate 648
-
3:05
checkmate 648: novel treatment for patients with advanced esophageal squamous cell carcinoma
-
1:22
3-year follow-up of checkmate 649: nivolumab chemotherapy in gc/gejc/eac
-
4:59
checkmate 648: 1l io-io in advanced esophageal squamous cell carcinoma
-
11:36
emerging data with immunotherapy in esophageal squamous cell carcinoma
-
9:32
checkmate 648: nivolumab plus ipilimumab or nivo plus chemo versus chemo as (1l) treatment for a...
-
2:10
checkmate 648: nivo chemo or ipi vs chemo as 1l treatment for advanced escc
-
4:58
long-term results from checkmate 040: nivolumab ipilimumab in advanced hcc
-
1:44
checkmate 649: nivolumab and chemotherapy or ipilimumab in gc/gejc/eac
-
6:23
checkmate 649 3-year follow-up: nivolumab plus chemotherapy for gastric and esophageal cancers
-
1:48
checkmate 205: 5 year follow-up of nivolumab in hl
-
13:47
checkmate 577 - is nivolumab adjuvant the standard of care in esophagus and gej?
-
1:15
dr. ferris on significance of checkmate-141 trial for head and neck cancer
-
1:35
checkmate 274: adjuvant nivolumab versus placebo for urothelial carcinoma
-
11:58
checkmate 214: nivolumab ipilimumab or sunitinib in patients with advanced renal cell carcinoma
-
1:58
who benefits from immunotherapy in patients with advanced escc?
-
3:59
checkmate 067 - combined nivolumab and ipilimumab